drugset
drugset / Trial / NCT03860207

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

NCT03860207 ↗

Phase 1/2 Terminated 12 enrolled Y-mAbs Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).

Timeline

Start
2019-02-22
Primary completion
2021-10-20
Completion
2021-10-20

Outcome

Outcome not reported

Stopped (Business): “study terminated due to business priorities”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Humanized 3F8 Bispecific Antibody Unknown — Intravenous

Indications

neuroblastoma osteosarcoma